Well-established industry leader whose oncology expertise and transactions record has led to multiple approved therapeutic ...

Naturally, the pharma industry has seen an explosion of mAbs in the pipeline, which has led to the evolution of new methods for improving and refining the antibody pipeline. Artificial ...

TIGIT, in particular, has proved to be a tricky target for drug developers, and BeiGene's decision comes just a few months after MSD abandoned the development of its anti-TIGIT antibody ...

The adhesion of cells to the surrounding extracellular matrix and their stimulation by soluble growth factors provide the environmental cues necessary to control a cell's decision to survive ...